Saxena White P.A. Files Securities Fraud Class Action Against Integer Holdings Corporation and Certain of Its Executives

Core Viewpoint - A securities fraud class action lawsuit has been filed against Integer Holdings Corporation and certain executives, alleging misleading statements and failure to disclose adverse facts about the company's business and operations during the class period from July 25, 2024, to October 22, 2025 [1] Company Overview - Integer Holdings Corporation, based in Plano, Texas, is one of the largest medical device contract development and manufacturing organizations globally, focusing on cardiac rhythm management and cardiovascular medical devices [2] - Approximately 60% of Integer's total revenue is generated from its cardiovascular product line, which includes electrophysiology devices that diagnose and map the heart's electrical activity [2] Industry Context - Prior to the class period, the electrophysiology device market experienced a technological revolution with the development of pulse field ablation procedures, which treat atrial fibrillation [3] - The integration of electrophysiology devices and pulse field ablation platforms became a significant growth driver for Integer's cardiovascular segment [3] Allegations in the Class Action - The lawsuit claims that during the class period, Integer's executives made materially false and misleading statements regarding the company's competitive position and sales performance in the electrophysiology market [4] - Specific allegations include: 1. Integer overstated its competitive position in the EP manufacturing market 2. The company experienced a deterioration in sales for two of its EP devices, contrary to claims of strong customer demand 3. Integer mischaracterized its EP devices as a long-term growth driver for its cardiovascular segment [4] Disclosure of Financial Performance - On October 23, 2025, Integer disclosed a lowered full-year 2025 sales guidance of $1.840 billion to $1.854 billion, which was below analysts' expectations [5] - The company projected net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, with expectations of declining sales for three new products, including two electrophysiology products [5] - Following this disclosure, Integer's stock price fell by $35.22, or over 32%, from $109.11 to $73.89 per share [5]